Immutep Ltd

Immutep operates with a highly liquid capital structure, as evidenced by a current ratio of 11.69, indicating strong short-term liquidity. The company holds cash and equivalents of AUD 17.26 million, while its total liabilities amount to only AUD 13.35 million. The debt-to-equity ratio is 0.01, suggesting minimal leverage and a conservative capital structure. The price-to-book ratio of 0.44 and price-to-tangible-book ratio of 0.44 further indicate that the company is trading at a significant discount to its book value.

Profitability metrics show that Immutep is currently unprofitable, with a net loss of AUD 61.43 million and an operating loss of AUD 70.14 million. The return on equity (ROE) is -42.77%, and the return on assets (ROA) is -39.13%, both of which are well below the typical thresholds for profitable operations in the biotechnology sector. The company's enterprise value to revenue ratio is 800.18, which is extremely high and suggests that the company is not currently generating sufficient revenue to justify its valuation.

Geographically and segment-wise, Immutep's revenue is not disclosed by region or business segment in the available data. However, the company's operations are primarily focused on the development of immunotherapies, which are likely to be marketed globally. The lack of segment-specific data limits the ability to assess geographic or product concentration risks.

The company's growth trajectory is currently constrained by its negative operating and net income. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability. The company's high valuation multiples, such as the EV/Revenue of 800.18, suggest that the market is betting on future growth rather than current performance. However, without a clear path to profitability or revenue expansion, the sustainability of this valuation is questionable.

Risk factors for Immutep include its unprofitable operations and the high valuation multiples that may not be supported by current financial performance. The company's liquidity is currently low, and while there are no immediate filing-based liquidity or dilution flags, the potential for future dilution remains a concern. The company's reliance on research and development for future growth introduces additional uncertainty, as clinical trials and regulatory approvals are inherently risky.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's price targets from analysts are uniformly set at 9.72 AUD, with a mean recommendation of 3.00, indicating a "hold" rating. The absence of strong buy or buy recommendations suggests that analysts are cautious about the company's near-term prospects.

Immutep Ltd (IMMP.O) has recorded a notable addition to its shareholder base, with a new investor acquiring a position as of March 31, 2026. This change, detected on June 20, 2026, marks the first analysis for this ticker, meaning there is no prior basis for computing delta changes against previous periods. The new holder, identified by investor ID 471, purchased 18,722 shares. The total value of this position is reported at $0.006571 million. Despite the acquisition, the holding represents a negligible weight of approximately 0.0000004% of the company's total equity, indicating a very small fractional stake relative to the broader market capitalization. This development occurs within a company structure that currently lists one officer and is followed by five analysts. Immutep Ltd is not a member of any major indices and has six top holders recorded in the system. The presence of analyst coverage suggests ongoing professional scrutiny of the firm's financials and estimates, even as institutional or significant holder activity remains limited. The significance of this signal lies in its nature as an initial data point rather than a shift in existing sentiment. With no prior basis for comparison, this addition serves as a baseline for future monitoring of holder changes. Investors should view this as the start of a tracking record for Immutep Ltd, with future updates required to determine if this represents a trend in accumulation or a one-off transaction.